Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

NCT ID: NCT01348516

Last Updated: 2012-07-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 83 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31

Brief Summary

The purpose of this study is to investigate the safety and pharmacokinetics of KM-023 after single/multiple dosing.

Conditions

Human Immunodeficiency Virus

Keywords

HIV

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

KM-023

Group Type: EXPERIMENTAL

KM-023

Intervention Type: DRUG

-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.

Placebo for KM-023

Group Type: PLACEBO_COMPARATOR

Placebo for KM-023

Intervention Type: DRUG

-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.

Interventions

KM-023

-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.

Intervention Type: DRUG

Placebo for KM-023

-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject is informed of the investigational nature of this study and voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB) - approved informed consent prior to performing any of the screening procedures
• Male or female between 20 and 45 years of age at the time of screening, inclusive
• A subject with body weight ≥ 45 kg and body mass index (BMI) between 18.5 and 25 (inclusive). - BMI (kg/m2) = weight (kg) / {height (m)}2
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion Criteria

1. A subject with a history of allergies to drugs (aspirin, antibiotics, etc.), or history of clinically significant allergies

2. A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease

3. A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug

4. A female subject who is pregnant, nursing mother, or sexually active females (childbearing potential)

5. Patients who are taking any of the following medications; Bepridil, cisapride, midazolam, pimozide, triazolam, Ergot medications (e.g. Wigraine, cafergot, St. John's wort), Phenobarbitol

6. Patients who have previously demonstrated hypersensitivity to Efavirenz or to one of the components of Stocrin or Sustiva

7. A positive Hepatitis B surface antigen or positive Hepatitis C antibody at screening.

8. A positive test for HIV antibody (as per local practice)

9. A subject who has taken any prescribed medication or herbal compounds within 14 days prior to the study drug administration. In addition, a subject who has taken any over-the-counter drug or vitamin supplements within 7 days prior to the study drug administration.

10. A subject who has participated in any other clinical trial either for investigational or marketed drugs within 8 weeks before the study drug administration

11. A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to start of administration of study drug

12. The value of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is greater than 1.25 times the upper limit of the reference range.

13. A subject who is unable to abstain from drinking alcoholic beverages throughout the study period.

14. A subject with a history of drug abuse, or a positive urine drug screening test

15. A subject who heavily takes caffeine or caffeine-containing products, or takes grapefruit, grapefruit juice, or grapefruit-containing products

16. A subject who is unable to eat a standardized meal offered by the study center

17. A subject who will be previously assigned to treatment during this study (except those who did not take any study medications)

18. Systolic blood pressure outside the range of 80 to 140 mm Hg, or diastolic blood pressure outside the range of 60 to 85 mm Hg, or heart rate outside the range of 50 to 100 beats per minute (bpm) for females; outside and the range of 45 to 100 beats per minute (bpm) for male subjects. Blood pressure and heart rate should be taken after 10 minutes of rest.

19. The investigator judges the subject not eligible for the study after reviewing clinical laboratory results or other reasons

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Kainos Medicine Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinical Trials Center, Seoul National University Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

KMCP-023-101

Identifier Type: -

Identifier Source: org_study_id